An open-label study of the effect of first-line treatment with Avastin [bevacizumab] + Xelox [oxaliplatin + capecitabine], followed by Avastin + Tarceva [erlotinib], on progression-free survival in patients with metastatic colorectal cancer

Trial Profile

An open-label study of the effect of first-line treatment with Avastin [bevacizumab] + Xelox [oxaliplatin + capecitabine], followed by Avastin + Tarceva [erlotinib], on progression-free survival in patients with metastatic colorectal cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Feb 2015

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine; Erlotinib; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 10 Aug 2012 Planned end date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
    • 14 Mar 2012 Status changed from active, no longer recruiting to completed, according to the European Clinical Trials Database.
    • 19 Sep 2011 Planned end date changed from 1 Jun 2010 to 1 Dec 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top